A dual negative regulation model of Toll-like receptor 4 signaling for endotoxin preconditioning in human endotoxemia

Mathematical Biosciences

Volumn 232, Issue 2, 2011, Pages 151-163

  Yang, Qian ^a   Calvano, Steven E ^b   Lowry, Stephen F ^b   Androulakis, Ioannis P ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Endotoxin; Humans; Lipopolysaccharide; Mathematical modeling; Potentiation; Tolerance

Indexed keywords

ENDOTOXIN; HUMANS; LIPOPOLYSACCHARIDES; MATHEMATICAL MODELING; POTENTIATION; TOLERANCE;

EXPERIMENTS; FEEDBACK; GENES;

SIGNALING;

ENDOTOXIN; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 10 RECEPTOR BETA; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

INHIBITOR; NUMERICAL MODEL; TOLERANCE;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTOXEMIA; ENZYME REGULATION; GENE TRANSLOCATION; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; INNATE IMMUNITY; MOLECULAR DYNAMICS; NEGATIVE FEEDBACK; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

COMPUTER SIMULATION; ENDOTOXEMIA; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LIPOPOLYSACCHARIDES; MODELS, BIOLOGICAL; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 79960132229     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2011.05.005     Document Type: Article

References (65)

1. Karima R., Matsumoto S., Higashi H., Matsushima K. The molecular pathogenesis of endotoxic shock and organ failure. Mol. Med. Today 1999, 5:123.
2. West M.A., Heagy W. Endotoxin tolerance: a review. Crit. Care Med. 2002, 30:S64.
3. Riviere B., Epshteyn Y., Swigon D., Vodovotz Y. A simple mathematical model of signaling resulting from the binding of lipopolysaccharide with Toll-like receptor 4 demonstrates inherent preconditioning behavior. Math. Biosci. 2009, 217:19.
4. Cavaillon J.M. The nonspecific nature of endotoxin tolerance. Trends Microbiol. 1995, 3:320.
5. Ziegler-Heitbrock H.W. Molecular mechanism in tolerance to lipopolysaccharide. J. Inflamm. 1995, 45:13.
6. Haas J.G., Baeuerle P.A., Riethmuller G., Ziegler-Heitbrock H.W. Molecular mechanisms in down-regulation of tumor necrosis factor expression. Proc. Natl. Acad. Sci. USA 1990, 87:9563.
7. Ziegler-Heitbrock H.W., Blumenstein M., Kafferlein E., Kieper D., Petersmann I., Endres S., Flegel W.A., Northoff H., Riethmuller G., Haas J.G. In vitro desensitization to lipopolysaccharide suppresses tumour necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology 1992, 75:264.
8. Munoz C., Carlet J., Fitting C., Misset B., Bleriot J.P., Cavaillon J.M. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 1991, 88:1747.
9. Day J., Rubin J., Vodovotz Y., Chow C.C., Reynolds A., Clermont G. A reduced mathematical model of the acute inflammatory response II. Capturing scenarios of repeated endotoxin administration. J. Theor. Biol. 2006, 242:237.
10. Vasilescu C., Olteanu M., Flondor P. How relevant are in vivo and in vitro studies for clinical sepsis? A mathematical model of LPS signaling based on endotoxin tolerance. Chirurgia (Bucur) 2009, 104:195.
11. An G. A model of TLR4 signaling and tolerance using a qualitative particle-event-based method: introduction of spatially configured stochastic reaction chambers (SCSRC). Math. Biosci. 2009, 217:43.
12. An G.C., Faeder J.R. Detailed qualitative dynamic knowledge representation using a BioNetGen model of TLR-4 signaling and preconditioning. Math. Biosci. 2009, 217:53.
13. Vodovotz Y., Constantine G., Rubin J., Csete M., Voit E.O., An G. Mechanistic simulations of inflammation: current state and future prospects. Math. Biosci. 2009, 217:1.
14. Berg D.J., Kuhn R., Rajewsky K., Muller W., Menon S., Davidson N., Grunig G., Rennick D. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 1995, 96:2339.
15. Fan H., Cook J.A. Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 2004, 10:71.
16. Draisma A., van der Hoeven J.G., Pickkers P. Endotoxin Tolerance. Mechanisms and Clinical Applicability. Yearbook of Intensive care and Emergency Medicine 2009, vol. 2009:51-58. Springer-Verlag, Berlin, Heidelberg, New York.
17. Takeda K., Akira S. TLR signaling pathways. Semin. Immunol. 2004, 16:3.
18. Liew F.Y., Xu D., Brint E.K., O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 2005, 5:446.
19. Janssens S., Burns K., Tschopp J., Beyaert R. Regulation of interleukin-1- and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88. Curr. Biol. 2002, 12:467.
20. Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 2003, 197:263.
21. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A., Medzhitov R., Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110:191.
22. Burns K., Clatworthy J., Martin L., Martinon F., Plumpton C., Maschera B., Lewis A., Ray K., Tschopp J., Volpe F. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat. Cell Biol. 2000, 2:346.
23. Kinjyo I., Hanada T., Inagaki-Ohara K., Mori H., Aki D., Ohishi M., Yoshida H., Kubo M., Yoshimura A. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 2002, 17:583.
24. Nakagawa R., Naka T., Tsutsui H., Fujimoto M., Kimura A., Abe T., Seki E., Sato S., Takeuchi O., Takeda K., Akira S., Yamanishi K., Kawase I., Nakanishi K., Kishimoto T. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002, 17:677.
25. Weichhart T., Saemann M.D. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann. Rheum. Dis. 2008, 67(Suppl. 3):iii70.
26. Shaw L.M., Rabinovitz I., Wang H.H., Toker A., Mercurio A.M. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 1997, 91:949.
27. Cardona-Gomez G.P., Mendez P., Garcia-Segura L.M. Synergistic interaction of estradiol and insulin-like growth factor-I in the activation of PI3K/Akt signaling in the adult rat hypothalamus. Brain Res. Mol. Brain Res. 2002, 107:80.
28. Hirsch E., Katanaev V.L., Garlanda C., Azzolino O., Pirola L., Silengo L., Sozzani S., Mantovani A., Altruda F., Wymann M.P. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000, 287:1049.
29. Huang F., Kao C.Y., Wachi S., Thai P., Ryu J., Wu R. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J. Immunol. 2007, 179:6504.
30. Okada T., Maeda A., Iwamatsu A., Gotoh K., Kurosaki T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 2000, 13:817.
31. Guha M., Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem. 2002, 277:32124.
32. Fukao T., Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol. 2003, 24:358.
33. Cobb J.P., Mindrinos M.N., Miller-Graziano C., Calvano S.E., Baker H.V., Xiao W., Laudanski K., Brownstein B.H., Elson C.M., Hayden D.L., Herndon D.N., Lowry S.F., Maier R.V., Schoenfeld D.A., Moldawer L.L., Davis R.W., Tompkins R.G., Baker H.V., Bankey P., Billiar T., Brownstein B.H., Calvano S.E., Camp D., Chaudry I., Cobb J.P., Davis R.W., Elson C.M., Freeman B., Gamelli R., Gibran N., Harbrecht B., Hayden D.L., Heagy W., Heimbach D., Herndon D.N., Horton J., Hunt J., Laudanski K., Lederer J., Lowry S.F., Maier R.V., Mannick J., McKinley B., Miller-Graziano C., Mindrinos M.N., Minei J., Moldawer L.L., Moore E., Moore F., Munford R., Nathens A., O'Keefe G., Purdue G., Rahme L., Remick D., Sailors M., Schoenfeld D.A., Shapiro M., Silver G., Smith R., Stephanopoulos G., Stormo G., Tompkins R.G., Toner M., Warren S., West M., Wolfe S., Xiao W., Young V. Application of genome-wide expression analysis to human health and disease. Proc. Natl. Acad. Sci. USA 2005, 102:4801.
34. Calvano S.E., Xiao W., Richards D.R., Felciano R.M., Baker H.V., Cho R.J., Chen R.O., Brownstein B.H., Cobb J.P., Tschoeke S.K., Miller-Graziano C., Moldawer L.L., Mindrinos M.N., Davis R.W., Tompkins R.G., Lowry S.F. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032.
35. Storey J.D., Xiao W., Leek J.T., Tompkins R.G., Davis R.W. Significance analysis of time course microarray experiments. Proc. Natl. Acad. Sci. USA 2005, 102:12837.
36. Alvarez S.M., Katsamanis Karavidas M., Coyle S.M., Lu S.E., Macor M., Oikawa L.O., Lehrer P.M., Calvano S.E., Lowry S.F. Low-dose steroid alters in vivo endotoxin-induced systemic inflammation but does not influence autonomic dysfunction. J. Endotoxin Res. 2007, 13:358.
37. Barber A.E., Coyle S.M., Marano M.A., Fischer E., Calvano S.E., Fong Y., Moldawer L.L., Lowry S.F. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J. Immunol. 1993, 150:1999.
38. Foteinou P.T., Calvano S.E., Lowry S.F., Androulakis I.P. In silico simulation of corticosteroids effect on an NFκB- dependent physicochemical model of systemic inflammation. PLoS One 2009, 4:e4706.
39. Wells C.A., Ravasi T., Hume D.A. Inflammation suppressor genes: please switch out all the lights. J. Leukoc. Biol. 2005, 78:9.
40. Krzyzanski W., Jusko W.J. Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 1997, 25:107.
41. Kawai T., Takeuchi O., Fujita T., Inoue J., Muhlradt P.F., Sato S., Hoshino K., Akira S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 2001, 167:5887.
42. Yamamoto M., Sato S., Hemmi H., Sanjo H., Uematsu S., Kaisho T., Hoshino K., Takeuchi O., Kobayashi M., Fujita T., Takeda K., Akira S. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002, 420:324.
43. Medzhitov R., Preston-Hurlburt P., Kopp E., Stadlen A., Chen C., Ghosh S., Janeway C.A. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 1998, 2:253.
44. Akira S. Toll-like receptor signaling. J. Biol. Chem. 2003, 278:38105.
45. Hu X., Chakravarty S.D., Ivashkiv L.B. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol. Rev. 2008, 226:41.
46. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997, 336:1066.
47. Kitano H. Systems biology: a brief overview. Science 2002, 295:1662.
48. Ojaniemi M., Glumoff V., Harju K., Liljeroos M., Vuori K., Hallman M. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur. J. Immunol. 2003, 33:597.
49. Zacharioudaki V., Androulidaki A., Arranz A., Vrentzos G., Margioris A.N., Tsatsanis C. Adiponectin promotes endotoxin tolerance in macrophages by inducing IRAK-M expression. J. Immunol. 2009, 182:6444.
50. Escoll P., del Fresno C., Garcia L., Valles G., Lendinez M.J., Arnalich F., Lopez-Collazo E. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem. Biophys. Res. Commun. 2003, 311:465.
51. Covert M.W., Leung T.H., Gaston J.E., Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 2005, 309:1854.
52. de Vos A.F., Pater J.M., van den Pangaart P.S., de Kruif M.D., van 't Veer C., van der Poll T. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J. Immunol. 2009, 183:533.
53. van 't Veer C., van den Pangaart P.S., van Zoelen M.A., de Kruif M., Birjmohun R.S., Stroes E.S., de Vos A.F., van der Poll T. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J. Immunol. 2007, 179:7110.
54. Wiersinga W.J., van't Veer C., van den Pangaart P.S., Dondorp A.M., Day N.P., Peacock S.J., van der Poll T. Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit. Care Med. 2009, 37:569.
55. Lu Y.C., Yeh W.C., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42:145.
56. Sun Y.N., Jusko W.J. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J. Pharm. Sci. 1998, 87:732.
57. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2001, 17:615.
58. Liu H., Perlman H., Pagliari L.J., Pope R.M. Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages Role of Mcl-1, independent of nuclear factor (NF)-kappaB, Bad, or caspase activation. J. Exp. Med. 2001, 194:113.
59. Chrysikopoulos C.V., Hsuan P.Y., Fyrillas M.M. Bootstrap estimation of the mass transfer coefficient of a dissolving nonaqueous phase liquid pool in porous media. Water Resour. Res. 2002, 38.
60. Foteinou P.T., Calvano S.E., Lowry S.F., Androulakis I.P. Modeling endotoxin-induced systemic inflammation using an indirect response approach. Math. Biosci. 2009, 217:27.
61. Efron B., Tibshirani R. An Introduction to the Bootstrap 1993, Chapman and Hall, New York.
62. Goldring C.E., Reveneau S., Pinard D., Jeannin J.F. Hyporesponsiveness to lipopolysaccharide alters the composition of NF-kappaB binding to the regulatory regions of inducible nitric oxide synthase gene. Eur. J. Immunol. 1998, 28:2960.
63. Cavaillon J.M., Adrie C., Fitting C., Adib-Conquy M. Reprogramming of circulatory cells in sepsis and SIRS. J. Endotoxin Res. 2005, 11:311.
64. Brint E.K., Xu D., Liu H., Dunne A., McKenzie A.N., O'Neill L.A., Liew F.Y. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 2004, 5:373.
65. Androulidaki A., Iliopoulos D., Arranz A., Doxaki C., Schworer S., Zacharioudaki V., Margioris A.N., Tsichlis P.N., Tsatsanis C. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31:220.